Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation

C. Davies, Jane; Wainwright, Claire; J. Canny, Gerard; Chilvers, Mark; S. Howenstine, Michelle; Munck, À.; G. Mainz, Jochen; Rodriguez, Sally; Li, Haihong; Yen, Karl; L. Ordoñez, Claudia; C. Ahrens, Richard

doi:10.1164/rccm.201301-0153oc

Public

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

Published in American Journal of Respiratory and Critical Care Medicine • May 23, 2013

Authors:

Jane C. Davies

Claire Wainwright

Gerard J. Canny

Abstract

RATIONALE: Ivacaftor (VX-770), a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been shown to improve lung function, pulmonary exacerbation rate, respiratory symptoms, and weight gain compared with placebo in patients with cystic fibrosis aged 12 years or older with a G5...

Subject

Ivacaftor

Medicine

Cystic fibrosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!